STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Cantargia AB (“Cantargia”) will be presenting new data at the Protein & Antibody Engineering Summit (“PEGS (http://www.pegsummiteurope.com/)”), an international scientific conference to be held in Lisbon, Portugal, from October 31st to November 4th 2016. The company will be presenting data from preclinical studies in non-small cell lung cancer, where the product candidate CAN04, a humanised antibody against the IL1RAP target molecule, has been investigated. The presentation will take place on October 31st 2016.
With the ambition of developing a new cancer therapy, Cantargia has developed a fully humanised antibody, CAN04, which binds with high affinity to Interleukin-1 Receptor Associated Protein (“IL1RAP”). The antibody blocks signalling from the inflammatory cytokine IL-1, which in turn reduces signals that promote tumour growth and survival. Cantargia has previously shown that antibodies against IL1RAP can stimulate killing of tumour cells in various preclinical PDX-models of leukemia.
In the new study Cantargia shows that high levels of IL1RAP are expressed also in several different solid tumours, including non-small cell lung cancer. CAN04 treatment of various solid tumour cell lines with IL1RAP on the cell surface led to a reduced secretion of the inflammatory and tumorigenic cytokines IL-6 and IL-8. CAN04 also stimulated cells from the immune system to directly destroy these tumour cells. In a PDX model, mice were transplanted directly with tumour cells from a patient with non-small cell lung cancer. In this model a microenvironment is developed in the tumour that is not obtained in classical cell line-based models. A statistically significant treatment effect was obtained with CAN04 in the study.
“We are very pleased to present new data on CAN04 at an important scientific conference. In addition to the documented effect in various models of non-small cell lung cancer, including a very aggressive PDX model, these results constitute an important base for continued studies of CAN04 both as monotherapy and in combination with other drugs”, Göran Forsberg, CEO, says.
The poster, The CAN04 antibody targets IL1RAP and inhibits tumor growth in a PDX model for NSCLC, will be available at www.cantargia.com after the presentation.
This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 20 October 2016, at 08.30.
This information was brought to you by Cision http://news.cision.com